Nanomedicine in pulmonary delivery

Heidi M Mansour, Yun-Seok Rhee, Xiao WuUniversity of Kentucky, College of Pharmacy, Division of Pharmaceutical Sciences-Drug Development Division, Lexington, KY, USAAbstract: The lung is an attractive target for drug delivery due to noninvasive administration via inhalation aerosols, avoidance of fi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Heidi M Mansour, Yun-Seok Rhee, Xiao Wu
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/ff97a35e4408448295ebd08459f80133
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ff97a35e4408448295ebd08459f80133
record_format	dspace
spelling	oai:doaj.org-article:ff97a35e4408448295ebd08459f801332021-12-02T07:21:17ZNanomedicine in pulmonary delivery1176-91141178-2013https://doaj.org/article/ff97a35e4408448295ebd08459f801332009-12-01T00:00:00Zhttp://www.dovepress.com/nanomedicine-in-pulmonary-delivery-a3806https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Heidi M Mansour, Yun-Seok Rhee, Xiao WuUniversity of Kentucky, College of Pharmacy, Division of Pharmaceutical Sciences-Drug Development Division, Lexington, KY, USAAbstract: The lung is an attractive target for drug delivery due to noninvasive administration via inhalation aerosols, avoidance of first-pass metabolism, direct delivery to the site of action for the treatment of respiratory diseases, and the availability of a huge surface area for local drug action and systemic absorption of drug. Colloidal carriers (ie, nanocarrier systems) in pulmonary drug delivery offer many advantages such as the potential to achieve relatively uniform distribution of drug dose among the alveoli, achievement of improved solubility of the drug from its own aqueous solubility, a sustained drug release which consequently reduces dosing frequency, improves patient compliance, decreases incidence of side effects, and the potential of drug internalization by cells. This review focuses on the current status and explores the potential of colloidal carriers (ie, nanocarrier systems) in pulmonary drug delivery with special attention to their pharmaceutical aspects. Manufacturing processes, in vitro/in vivo evaluation methods, and regulatory/toxicity issues of nanomedicines in pulmonary delivery are also discussed.Keywords: pulmonary delivery, colloidal carriers, nanocarrier systems, liposome, polymeric nanoparticle, solid lipid nanoparticle, submicron emulsion, dendrimer Heidi M MansourYun-Seok RheeXiao WuDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2009, Iss default, Pp 299-319 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Heidi M Mansour Yun-Seok Rhee Xiao Wu Nanomedicine in pulmonary delivery
description	Heidi M Mansour, Yun-Seok Rhee, Xiao WuUniversity of Kentucky, College of Pharmacy, Division of Pharmaceutical Sciences-Drug Development Division, Lexington, KY, USAAbstract: The lung is an attractive target for drug delivery due to noninvasive administration via inhalation aerosols, avoidance of first-pass metabolism, direct delivery to the site of action for the treatment of respiratory diseases, and the availability of a huge surface area for local drug action and systemic absorption of drug. Colloidal carriers (ie, nanocarrier systems) in pulmonary drug delivery offer many advantages such as the potential to achieve relatively uniform distribution of drug dose among the alveoli, achievement of improved solubility of the drug from its own aqueous solubility, a sustained drug release which consequently reduces dosing frequency, improves patient compliance, decreases incidence of side effects, and the potential of drug internalization by cells. This review focuses on the current status and explores the potential of colloidal carriers (ie, nanocarrier systems) in pulmonary drug delivery with special attention to their pharmaceutical aspects. Manufacturing processes, in vitro/in vivo evaluation methods, and regulatory/toxicity issues of nanomedicines in pulmonary delivery are also discussed.Keywords: pulmonary delivery, colloidal carriers, nanocarrier systems, liposome, polymeric nanoparticle, solid lipid nanoparticle, submicron emulsion, dendrimer
format	article
author	Heidi M Mansour Yun-Seok Rhee Xiao Wu
author_facet	Heidi M Mansour Yun-Seok Rhee Xiao Wu
author_sort	Heidi M Mansour
title	Nanomedicine in pulmonary delivery
title_short	Nanomedicine in pulmonary delivery
title_full	Nanomedicine in pulmonary delivery
title_fullStr	Nanomedicine in pulmonary delivery
title_full_unstemmed	Nanomedicine in pulmonary delivery
title_sort	nanomedicine in pulmonary delivery
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/ff97a35e4408448295ebd08459f80133
work_keys_str_mv	AT heidimmansour nanomedicineinpulmonarydelivery AT yunseokrhee nanomedicineinpulmonarydelivery AT xiaowu nanomedicineinpulmonarydelivery
_version_	1718399497214623744

Nanomedicine in pulmonary delivery

Ejemplares similares